I. Call to Order………………………………………………………………………Marty McKay

II. Parliamentary Business ..............................................................................Marty McKay
   A. Introduction of Members/Roll Call and DHH Staff
   B. Approval of October 29, 2014 Meeting Minutes

III. Ethics Reminders......................................................................................Kim Sullivan

IV. Managed Care Update..............................................................................Mary T.C. Johnson

V. Reports.......................................................................................................Melwyn Wendt
   A. Prior Authorization Monthly Report
   B. PDL Reflecting October 29, 2014 P&T Committee Recommendations
   C. Louisiana Medicaid Preferred Drug List Program Overview and Results Report – January 2015

VI. New Business..............................................................................................Julie Pritchard
   A. Therapeutic Class Reviews/Drug Manufacturer Testimony
      1. Analgesics, Narcotics Long
      2. Analgesics, Narcotics Short
      3. Angiotensin Modulator Combinations
      4. Angiotensin Modulators
      5. Antibiotics, GI
      6. Antibiotics, Inhaled
      7. Antibiotics, Topical
      8. Antibiotics, Vaginal
      9. Anticoagulants
     10. Antiemetic/Antivertigo Agents
     11. Antifungals, Oral
     12. Antifungals, Topical
     13. Antimigraine Agents, Triptans
     14. Antiparasitics, Topical
     15. Antivirals, Topical
     16. Beta-Blockers
     17. Bladder Relaxant Preparations
     18. Bone Resorption Suppression and Related Agents
     19. BPH Treatments
     20. Bronchodilators, Beta-Agonist
     21. Calcium Channel Blockers
     22. Cephalosporins and Related Antibiotics
     23. Erythropoiesis Stimulating Proteins
     24. Fluoroquinolones, Oral
     25. Growth Hormone
26. Hepatitis C Agents
27. Hypoglycemics, Incretin Mimetics/Enhancers
28. Hypoglycemics, Insulin and Related Agents
29. Hypoglycemics, Meglitinides
30. Hypoglycemics, SGLT2
31. Hypoglycemics, TZD
32. Lincosamides/Oxazolidinones/Streptogramins
33. Lipotropics, Other
34. Lipotropics, Statins
35. Macrolides/Ketolides
36. Multiple Sclerosis Agents
37. PAH Agents, Oral and Inhaled
38. Pancreatic Enzymes
39. Phosphate Binders
40. Pituitary Suppressive Agents, LHRH
41. Platelet Aggregation Inhibitors
42. Proton Pump Inhibitors
43. Skeletal Muscle Relaxants
44. Tetracyclines
45. Ulcerative Colitis Agents

VII. New Single Drug Reviews in Current PDL Categories..........................Julie Pritchard
1. Antiparkinson’s Agents - Rytary
2. COPD Agents – Incruse Ellipta
3. COPD Agents – Spiriva Respimat
4. Cytokine and CAM Antagonists – Cosentyx Pen and Syringe
5. Emollients - Bionect
6. Glucocorticoids, Inhaled – Arnuity Ellipta
7. Glucocorticoids, Inhaled – Asmanex HFA
8. Ophthalmics for Allergic Conjunctivitis – Pazeo
9. Ophthalmics, Anti-Inflammatories – Iluvien
10. Sedative Hypnotics – Belsomra
11. Stimulants and Related Agents - Evekeo

VIII. Other Business

VIII. Next Steps
A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

IX. Next Meeting Date – October 27, 2015 or November 4, 2015

X. Public Testimony